8 Coupons
-
Special Offer
-
30% off
researchers examined 1,714 samples over six months and found that just 39 per cent contained what they buyer thought they had been sold
.
.eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.